Search for Clinical Trial Results
Lymphoma, Primary Effusion - 14 Studies Found
Status | Study |
Recruiting |
Study Name: Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Condition:
Interventions: |
Recruiting |
Study Name: Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Condition:
|
Recruiting |
Study Name: 124I-FIAU Imaging in EBV and KSHV Associated Cancers Condition:
Interventions: |
NOT_YET_RECRUITING |
Study Name: Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma Condition: Date: 2024-05-11 Interventions: Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses |